Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02131844
Other study ID # MUHC Study Code 13-329-SDR
Secondary ID Mitacs Elevate F
Status Completed
Phase N/A
First received March 28, 2014
Last updated March 2, 2018
Start date August 2014
Est. completion date May 2016

Study information

Verified date March 2018
Source McGill University Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Early mobilization (i.e. initiation of out of bed activities from the day of surgery) is considered an important component of postoperative care after colorectal surgery. Having a health professional dedicated to facilitate early mobilization has the potential to enhance postoperative recovery by preventing the negative effects of prolonged bed rest (e.g. increased risk for complications, muscle loss, deconditioning and functional decline); however, the need to implement this resource-intensive approach is not evidence based. This study aims to contribute evidence about the role of facilitated early mobilization as a strategy to enhance recovery after colorectal surgery.


Description:

The primary research question of this study is: to what extent does postoperative facilitation of early mobilization impact on recovery of functional walking capacity at 4 weeks after surgery in comparison to standard care (preoperative education).

The hypothesis is that, by 4 weeks after surgery, facilitated early mobilization will result in a greater proportion of participants returning to preoperative levels of functional walking, as measured by the six-minute walk test (6MWT).


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 2016
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult people (>18 years)

- Colonic or rectal diseases (i.e. cancer, inflammatory bowel disease, diverticulitis) planned for surgical resection

Exclusion Criteria:

- Metastatic disease

- Medical conditions that preclude postoperative mobilization (e.g. neurological or musculoskeletal diseases)

- Inability to understand English or French

- Admission to intensive care immediately after the surgery

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Facilitated early mobilization
Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
Usual care
Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)

Locations

Country Name City State
Canada Montreal General Hospital Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
McGill University Health Center Mitacs

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional walking capacity (six-minute walk test) The outcome of interest will be the proportion of participants returning to preoperative levels of functional walking capacity at 4 weeks after surgery (within an estimated measurement error of 20 meters) before surgery; 4 weeks after surgery
Secondary Time out of bed (sitting and standing) Measured by an activity monitor (Actigraph) worn over the participants' hip postoperative day (POD) 0, 1, 2 and 3
Secondary Time to readiness for discharge Time to achieve standardized hospital discharge criteria (tolerance of oral intake, recovery of lower gastrointestinal function, adequate pain control on oral analgesia, ability to mobilize and self care and no evidence of complications or untreated medical problems). duration of hospital stay (expected average of 3 days after surgery)
Secondary Time to recovery of gastrointestinal motility Time to achieve criteria for recovery of gastrointestinal transit (tolerance of solid diet and bowel movement) Expected average of 2 days after surgery
Secondary Postoperative fatigue (Multidimensional Fatigue Inventory) before surgery; POD 1, 2 and 3; 2 weeks after surgery; 4 weeks after surgery.
Secondary Self-reported physical activity status (Duke Activity Status Index) before surgery; 2 weeks after surgery; 4 weeks after surgery
Secondary Mobility (Life-Space Mobility Assessment) before surgery; 4 weeks after surgery
Secondary Condition-specific health-related quality of life (Abdominal Surgery Impact Scale) before surgery; POD 1, 2 and 3; 2 weeks after surgery; 4 weeks after surgery
Secondary Generic heath-related quality of life (RAND-36) before surgery; 4 weeks after surgery
Secondary Postoperative complications Classified according to Clavien-Dindo Index and converted into a continuous scale using the Comprehensive Complication Index up to 4 weeks after surgery
Secondary Pulmonary function (spirometry) Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and cough expiratory flow (CEF) will be recorded before surgery; POD 1, 2 and 3; 4 weeks after surgery
See also
  Status Clinical Trial Phase
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Terminated NCT01119027 - Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills N/A
Completed NCT01063231 - Evaluation of PillCamâ„¢ Colon 2 in Visualization of the Colon Phase 3
Completed NCT04074577 - Computer Aided Detection, Tandem Colonoscopy Study N/A
Not yet recruiting NCT04087824 - Deep Learning Algorithm for Recognition of Colonic Segments. N/A
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Terminated NCT02503631 - Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
Completed NCT01600209 - Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing N/A
Completed NCT01260168 - Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies N/A
Completed NCT00604162 - PillCamâ„¢ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon Phase 3
Recruiting NCT04598880 - Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing Phase 4
Completed NCT01738425 - A Clinical Phase I Study on GIC-1001 in Healthy Volunteers Phase 1
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02291445 - Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03139942 - Optical Polyp Testing for In Vivo Classification N/A
Completed NCT04263818 - Endoscopist and Endoscope Motions During Colonoscopy N/A
Recruiting NCT05923918 - A Study to Evaluate Safety and Efficacy of PBK_M2101 Phase 3
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2